

# Bio (Overweight)

David Kwon, Ph.D +822-768-3251 david.kwon@dwsec.com  
John Han +822-768-4179 john.han@dwsec.com

June 28, 2011  
Industry Report

## Stem cells: At the heart of the bio industry

- Hearticellgram-AMI: A bone marrow-derived stem cell therapy
- World's first approval of stem cell drug warrants reevaluation of autologous stem cell companies
- Focus on RNL Bio and FCB Twelve (autologous stem cell companies) and Medipost (thanks to Cartistem)


### ■ The world's first approval for a stem cell treatment seems imminent

On June 24<sup>th</sup>, it was reported that the Korean FDA is highly likely to approve Hearticellgram-AMI, a stem cell therapy developed by FCB-Pharmacell. This would mark the first approval of a stem cell treatment in history. Since the news broke, shares related to stem cell companies—including FCB Twelve (a parent company of FCB-Pharmacell), RNL Bio, and Medipost—have skyrocketed. This development is also forcing investors to pay greater attention to the bio industry in general. It seems that stem cells are now at the heart of the bio industry.

### ■ Hearticellgram-AMI

Hearticellgram-AMI is a stem cell treatment for acute myocardial infarction, derived from the patient's own bone marrow. The drug is made from mesenchymal stem cells (contained in bone marrow) which are separated and cultured for three to four weeks. The Hearticellgram-AMI is then injected directly into the patient's heart. According to FCB Twelve's Phase 3 clinical trial, patients who had undergone a cardiac angioplasty showed a 6% higher left ventricular ejection fraction (LVEF), six months after being injected with Hearticellgram-AMI.

Figure 1. Price trends of major domestic stem cell companies



Source: Daewoo Securities Research

Figure 2. Hearticellgram-AMI



Source: FCB Twelve

### ■ What would approval for a stem cell treatment mean?

1) Approval would confirm stem cells' potential for treating diseases that have been resistant to existing medical technologies and synthetic drugs.

2) Hearticellgram-AMI uses mesenchymal stem cells extracted from patients' own bone marrow. As a result, the therapy's toxicity levels are low, which should increase its commercial potential. Indeed, the use of patients' own tissues should grab greater attention.

3) Approval would likely expedite the legislative process of a National Assembly bill proposing a simplified clinical trial for stem cell therapies using patients' own tissues. The bill, which is still pending at the Health and Welfare Committee, is likely to receive a positive response.

### ■ Is a 6% higher LVEF good enough?

Some argue that a mere 6% increase in LVEF is disappointing given that the treatment is estimated to cost over W20mn. However, we believe the treatment is meaningful for the following reasons:

(1) Overcoming current limitations: Although a 6% improvement may be lower than expected, we find the treatment to be significant as it can overcome the limitations of current medical technology and synthetic drugs. Patients who have had heart surgery are keen to improve their LVEF, albeit slightly.

(2) Potential for further LVEF improvement: While the treatment is currently based on a single dose injection, a variety of other treatment procedures can be developed, making room for further LVEF improvement.

### ■ Keep an eye on potential risks

FCB-Pharmicell is expected to aim to attract 10% of Korea's myocardial infarction patients (currently around 65,000 per year) in the mid- to long-term. Although initial sales of Hearticellgram-AMI will not be covered by the national health insurance, the company is likely to attempt to add the treatment to the insurance coverage list. However, investors should keep an eye on the company's strategy and performance in light of potential risks, including: 1) the possibility that Hearticellgram-AMI's market share may only be 2~3%, 2) the company's potential failure to gain coverage for the therapy, and 3) marketing difficulties.

### ■ Focus on providers of autologous stem cell therapies

Autologous stem cell therapies (i.e. stem cells derived from patients' own bodies) are likely to draw keen attention, in light of: 1) their low toxicity levels and 2) favorable regulatory measures. Korea's major stem cell companies are RNL Bio (003190 KS), which focuses on adipose-derived stem cells, and FCB Twelve (005690 KS), which is likely to receive approval soon for its bone marrow-derived stem cell therapy.

Attention to Medipost (078160 KQ) should also remain steady, as the company is pushing to get approval for Cartistem, a rheumatoid arthritis treatment using human umbilical cord blood-derived stem cells. We expect this treatment to be approved in 2H11.

**Table 1. Clinical trial status for treatments of major domestic stem cell companies**

Company	Type of stem cell	Product name	Symptoms	Administration	Mechanism	Domestic development process	Expected domestic release
FCB-Pharmicell	Adult (autologous, bone marrow)	Hearticellgram-AMI	Myocardial infarction	Surgery	Heart cell regeneration	Approval	2011
FCB-Pharmicell	Adult (autologous, bone marrow)	MSC1	Acute cerebral infraction	Intravenous	Cerebral cell regeneration	Phase 3	2013
RNL Bio	Adult (autologous, adipose)	Vascostem	Buerger's disease	Intravenous	Blood vessel regeneration	Phase 2	2013
RNL Bio	Adult (autologous, adipose)	RNL-Jointstem	Osteoarthritis	Injection	Cartilage regeneration	Phase 1/2	2013
Medipost	Adult (allogeneic, cord blood)	Cartistem	Osteoarthritis	Surgery	Cartilage regeneration	Evaluation	2012

Source: Company data

### Important Disclosures & Disclaimers

As of the publication date, Daewoo Securities Co., Ltd and/or its affiliates do not have any special interest with the subject company and do not own 1% or more of the subject company's shares outstanding.

Analyst of the subject company or member of the analyst's household does not have any financial interest in the securities of the subject company and the nature of the financial interest (including without limitation, whether it consists of any option, right, warrant, future, long or short position).

This report reflects the sole opinion of the analyst without any external influences by third parties.

This report has been provided by the research division of Daewoo Securities Co., Ltd. The stock ratings, target prices, estimates and overall viewpoints are from the research division of Daewoo Securities. Investors can access Daewoo Securities' research directly through our website ([www.bestez.com](http://www.bestez.com)), FirstCall Research, Reuters, FnGuide, WiseFn, FactSet and Bloomberg (DWIR). This document was prepared by Daewoo Securities Co., Ltd. ("Daewoo"). Information and opinions contained herein have been compiled from sources believed to be reliable and in good faith. The information has not been independently verified. Daewoo makes no guarantee, representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the information and opinions contained in this document. Daewoo accepts no responsibility or liability whatsoever for any loss arising from the use of this document or its contents or otherwise arising in connection therewith. Information and opinions contained herein are subject to change without notice. This document is for information purposes only. It is not and should not be construed as an offer or solicitation of an offer to purchase or sell any securities or other financial instruments. This document may not be reproduced, further distributed or published in whole or in part for any purpose. Daewoo and/or other affiliate companies, their directors, representatives, or employees may have long or short positions in any of the securities or other financial instruments mentioned in this document or issuers described herein at any time and may purchase and/or sale, or offer to purchase and/or sale such securities or other financial instruments in the open market or otherwise, in each case either as principal or agent. This document is for distribution within the United Kingdom to persons authorized under the Financial Services Act 1986. Daewoo Securities is the sole provider of information contained in this document. Daewoo's U.S. affiliate, Daewoo Securities (America) Inc., a member of FINRA/SIPC, is the sole distributor of this document within the U.S. This document may be distributed in the U.S. only to major U.S. institutional investors as defined in Rule 15a-6 of the U.S. Securities Exchange Act of 1934. Any U.S. recipient of this document wishing to effect any transactions in any securities discussed herein should contact and place orders with Daewoo Securities (America) Inc.

### Daewoo Securities International Network

#### Daewoo Securities Co. Ltd. (Seoul)

Head Office  
31-3 Yeouido-dong, Yeongdeungpo-gu  
Seoul 150-716  
Korea  
Tel: 82-2-768-3026

#### Daewoo Securities (Europe) Ltd.

Tower 42, Level 41  
25 Old Broad Street  
London EC2N 1HQ  
United Kingdom  
Tel: 44-20-7982-8016

#### Shanghai Representative Office

Unit 13, 28<sup>th</sup> Floor, Hang Seng Bank Tower  
1000 Lujiazui Ring Road  
Pudong New Area, Shanghai 200120  
China  
Tel: 86-21-5013-6392

#### Daewoo Securities (Hong Kong) Ltd.

Two International Finance Centre  
Suites 2005-2012  
8 Finance Street, Central  
Hong Kong  
Tel: 85-2-2514-1304

#### Tokyo Representative Office

7th Floor, Yusen Building  
2-3-2 Marunouchi, Chiyoda-ku  
Tokyo 100-0005  
Japan  
Tel: 81-3-3211-5511

#### Ho Chi Minh Representative Office

Centec Tower  
72-74 Nguyen Thi Minh Khai Street  
Ward 6, District 3, Ho Chi Minh City  
Vietnam  
Tel: 84-8-3910-6000

#### Daewoo Securities (America) Inc.

600 Lexington Avenue  
Suite 301  
New York, NY 10022  
United States  
Tel: 1-212-407-1022

#### Beijing Representative Office

Suite 2602, Twin Towers (East)  
B-12 Jianguomenwai Avenue  
Chaoyang District, Beijing 100022  
China  
Tel: 86-10-6567-9699